Trial Profile
Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2014
Price :
$35
*
At a glance
- Drugs Octenidine/prednicarbate (Primary) ; Octenidine; Prednicarbate
- Indications Tinea pedis
- Focus Therapeutic Use
- Sponsors Almirall S.A.
- 12 May 2014 New trial record